Author Archives: Peter Megdal PhD

Cardiovascular prevention prioritizes proven interventions: cholesterol management, blood pressure control, smoking cessation, and lifestyle optimization. However, homocysteine is an additional modifiable risk factor—an amino acid linked to endothelial dysfunction and thrombosis. Supplements supplying the active cofactors for homocysteine metabolism—L-methylfolate (5-MTHF), methylcobalamin (active B-12), and pyridoxal-5-phosphate (P-5-P, active B-6)—reliably lower homocysteine levels. This Q&A explains the mechanism, the evidence regarding cardiovascular outcomes, product quality verification, and clinical integration.

Background: Coronary atherosclerosis, long thought to be an inexorably progressive disease, is now recognized as biologically reversible under specific metabolic and inflammatory conditions. Imaging studies using intravascular ultrasound (IVUS), coronary computed tomography angiography (CCTA), and quantitative coronary angiography (QCA) consistently demonstrate that aggressive lipid lowering or comprehensive lifestyle change can induce measurable regression of plaque burden. However, luminal area often fails to expand in parallel—a phenomenon termed the lumen paradox. For endurance athletes, who rely on high coronary flow reserve and robust endothelial responsiveness, understanding this paradox is crucial.